Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Страна 1 од 30 резултати
Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND
Antipsychotic augmentation is an effective treatment intervention for Obsessive Compulsive Disorder (OCD) patients resistant to Selective Serotonin Reuptake Inhibitors (SSRI) agents. This pilot study was conducted to evaluate the effectiveness and tolerability of Aripiprazole for the
[Aripiprazole - a medical treatment alternative for Tourette Syndrome in childhood and adolescence].
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
OBJECTIVE
We report a case-series of seven patients with a medical history of at least two years of tic disorder treated with the partial dopamine agonist aripiprazole to illustrate its efficacy as a treatment alternative for motor and vocal tics in children and adolescents.
METHODS
A case series of
Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Several double blind, prospective trials have demonstrated an antidepressant augmentation efficacy of aripiprazole in depressed patients unresponsive to standard antidepressant therapy. Although aripiprazole is now widely used for this indication, and much is known about its receptor-binding
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND
This post hoc analysis assessed the safety, tolerability and effectiveness of long-term treatment with aripiprazole adjunctive to either bupropion or selective serotonin reuptake inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitors (SNRIs) in patients with major depressive
Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND
We conducted a systematic review and meta-analysis of randomized controlled trials comparing aripiprazole with pooled antipsychotics in Japanese patients with schizophrenia.
METHODS
We performed a literature search of data published in PubMed(®), the Cochrane Library database, the Japan
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
OBJECTIVE
Safety and tolerability assessment of initiating treatment with a once monthly long-acting injectable form of aripiprazole (aripiprazole once monthly) in patients stabilized on oral antipsychotics other than aripiprazole.
METHODS
Patients with schizophrenia treated with oral atypical
Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
OBJECTIVE
The purpose of this study was to compare the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder (MDD) unresponsive to selective serotonin reuptake inhibitors (SSRIs).
METHODS
This is the first randomized, prospective, open-label,
Aripiprazole in youth with intellectual disabilities: A retrospective chart study.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
A retrospective chart study of patients on open-label aripiprazole treatment was conducted in the Netherlands to add to the knowledge of aripiprazole in children and young adults with mild and borderline intellectual disabilities (IDs). Fifty-three youths, mean age 14.7 ± 3.4 years and mean IQ 64.5
Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
OBJECTIVE
To test aripiprazole for efficacy in decreasing use in methamphetamine-dependent adults, compared to placebo.
METHODS
Participants were randomized to receive 12 weeks of aripiprazole or placebo, with a 3-month follow-up and a platform of weekly 30-minute substance abuse
Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
OBJECTIVE
The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD).
METHODS
Eleven subjects (10 males) with TD (age 9-19 years, mean 13.36, standard deviation [SD] 3.33) who
Aripiprazole: a dopamine modulator that mimics methylphenidate in producing faster antidepressant effects.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Up to 60% of depressed patients do not respond to two months of pharmacotherapy, and late treatment responses are often correlated with poor outcomes and may be characterized as treatment-resistant depression (TRD). Previous studies have noted that the addition of a psychostimulant such as
Aripiprazole-Induced Hoarseness: A Case Report.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Low-dose Aripiprazole Induced Enuresis Continuum in a Child
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Aripiprazole is an atypical antipsychotic commonly used in the treatment of childhood disorders, such as bipolar disorder, psychosis, and irritability associated with autism spectrum disorder. Common side effects of its use include extrapyramidal side effects, somnolence, tremor, fatigue, nausea,
Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
OBJECTIVE
To evaluate the safety and tolerability of aripiprazole adjunctive to standard antidepressant therapy (ADT) for patients with major depressive disorder (DSM-IV-TR criteria).
METHODS
Data from 2 identical studies of aripiprazole augmentation (8 weeks of prospective ADT treatment followed by
Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
OBJECTIVE
The purpose of this study was to evaluate the impact of prior antipsychotic exposure (PAE) on safety and tolerability outcomes in pediatric subjects receiving aripiprazole treatment.
METHODS
This study was a post-hoc analysis of pooled data from two 8-week, double-blind, randomized,
Најкомплетнија база лековитог биља подржана науком
- Ради на 55 језика
- Биљни лекови потпомогнути науком
- Препознавање биљака по слици
- Интерактивна ГПС мапа - означите биље на локацији (ускоро)
- Читајте научне публикације повезане са вашом претрагом
- Претражите лековито биље по њиховим ефектима
- Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима
Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима
